170 related articles for article (PubMed ID: 29648921)
21. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
22. [Chemotherapy in hormone refractory prostatic carcinoma].
Biedermann B; Pless M; Herrmann R
Dtsch Med Wochenschr; 1999 Jul; 124(28-29):874-9. PubMed ID: 10432951
[No Abstract] [Full Text] [Related]
23. Metastatic Prostate Cancer.
Sartor O; de Bono JS
N Engl J Med; 2018 Feb; 378(7):645-657. PubMed ID: 29412780
[No Abstract] [Full Text] [Related]
24. Cabazitaxel for castration-resistant prostate cancer.
Shigeta K; Miura Y; Naito Y; Takano T
Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
[No Abstract] [Full Text] [Related]
25. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
Caffo O; Veccia A; Kinspergher S; Maines F
Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
[TBL] [Abstract][Full Text] [Related]
26. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
27. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Gravis G; Marino P; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Fizazi K
Eur J Cancer; 2014 Mar; 50(5):953-62. PubMed ID: 24424105
[TBL] [Abstract][Full Text] [Related]
28. Is long-term androgen suppression right for everyone with locally advanced prostate cancer?
D'Amico AV
Lancet Oncol; 2010 Nov; 11(11):1016-7. PubMed ID: 20933467
[No Abstract] [Full Text] [Related]
29. [Monotherapy versus combined androgen blockade for advanced/metastatic prostate cancer].
Iida K
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2553-7. PubMed ID: 22189220
[TBL] [Abstract][Full Text] [Related]
30. The evolving role of chemotherapy in prostate cancer.
Boulos S; Mazhar D
Future Oncol; 2017 May; 13(12):1091-1095. PubMed ID: 28095710
[TBL] [Abstract][Full Text] [Related]
31. Current treatment of advanced prostate cancer.
Ismail M; Gomella LG
Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
[TBL] [Abstract][Full Text] [Related]
32. The treatment of hormone refractory prostate cancer.
Panvichian R; Pienta KJ
Compr Ther; 1996 Feb; 22(2):81-7. PubMed ID: 8689867
[No Abstract] [Full Text] [Related]
33. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
34. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
35. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N
BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of carcinoma of the prostate with analogs of LHRH].
Rubio Herrera MA; Calle Fernández JR
Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
[No Abstract] [Full Text] [Related]
37. [Complete androgen blockage in the treatment of metastatic prostate cancer].
Matzkin H; Braf Z
Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
[No Abstract] [Full Text] [Related]
38. [Drastic changes in the treatment of metastatic prostate cancer].
Thellenberg Karlsson C; Ståhl O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38651316
[TBL] [Abstract][Full Text] [Related]
39. Expanding treatment options for metastatic prostate cancer.
Antonarakis ES; Eisenberger MA
N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
[No Abstract] [Full Text] [Related]
40. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
Masson S; Bahl A
BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
